<DOC>
	<DOC>NCT01893125</DOC>
	<brief_summary>To investigate the effect of repeat oral dosing of CNV2197944 75 mg tid on the pain experienced in diabetic peripheral neuropathy (DPN) as measured by changes in PI-NRS after three weeks of treatment compared to the baseline period.</brief_summary>
	<brief_title>Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description>A 3 week randomised crossover study to investigate the effect of repeat oral dosing of CNV2197944 75 mg tid versus placebo for on the pain experienced in diabetic peripheral neuropathy (DPN). Each 3 week treatment period is seperated by a 2 week washout period. The primary outcome measure is the change from baseline in the PI-NRS after three weeks of treatment. Secondary outcome measures include pain responder rates, clinical and patient global impressions of pain, and the Neuropathic Pain Symptom Inventory.</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Male or female between 18 and 85 years of age inclusive, at the time of signing the informed consent Diabetes Mellitus (Type I or II)with HbA1c &lt;9% Evidence of symmetrical bilateral pain in lower limbs with evidence of decreased sensation or impaired reflexes and a Michigan Neuropathy Screening Instrument score of &gt;3 on physical examination Patients with diabetic peripheral neuropathy (DPN) with pain at screening present for more than 6 months. The maximum duration of DPN will be no longer than 5 years Patients having other severe pain, which may impair the selfassessment of the pain due to DPN Patients who have received nerve blocks for neuropathic pain within 4 weeks Patients on other concomitant medications used to relieve the pain of DPN Patients with a documented failure to respond to a maximally tolerated dose regimen of gabapentin or pregabalin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>